Dose reduction of glucocorticoids in systemic lupus erythematosus

As­traZeneca’s PD-L1 Imfinzi failed a Phase III tri­al in non-small cell lung can­cer (NSCLC) when in­ves­ti­gat­ed con­cur­rent­ly with chemora­dio­ther­a­py (CRT) as the com­pa­ny worked to

Rep. Frank Pal­lone (D-NJ) is call­ing on House Re­pub­li­cans to reau­tho­rize the Pan­dem­ic and All-Haz­ards Pre­pared­ness Act in a bid to ad­dress the near-record drug

Sands Cap­i­tal said Tues­day it closed a $555 mil­lion life sci­ences fund, mark­ing its third fund in the in­dus­try. The Ar­ling­ton, VA-based long-term in­vestor will